A team of cancer genomics scientists from The University of Manchester and The Institute of Cancer Research, London, ...

Immune checkpoint inhibitors have transformed cancer care, yet only a minority of patients respond to monotherapy, and immune-related adverse events remain a major concern.

Clonal hematopoiesis of indeterminate potential (CHIP) is increasingly recognized as a precursor state that predisposes individuals to myeloid malignancies ...